|
|
Article: Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting.
- Article from:
- Cancer Weekly
- Article date:
- November 10, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced that more than 25 studies evaluating the use of Nexavar=AE (sorafenib) tablets in liver cancer will be presented at The Liver Meeting=AE, the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nexavar is the only systemic treatment to demonstrate prolonged survival in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, and is currently approved in more than 80 countries for the treatment of the disease (see also Liver Cancer).
"Bayer and Onyx are committed to further evaluating Nexavar in patients ...
Related newspaper, magazine, and journal articles:
|
|
Article: Onyx Pharmaceuticals Reports Third Quarter and ...
Cancer Weekly;
November 18, 2008 ;
700+ words
... ... see also Onyx Pharmaceuticals, Inc ... treatment of liver cancer and advanced ... leadership in the liver cancer market with ... Kidney Cancer, Liver Cancer, Liver Carcinoma ... Oncology, Onyx Pharmaceuticals Inc., Pharmaceutical ...
|
|